318 related articles for article (PubMed ID: 15599706)
21. Inhibitory effects of berberine on IK1, IK, and HERG channels of cardiac myocytes.
Li BX; Yang BF; Zhou J; Xu CQ; Li YR
Acta Pharmacol Sin; 2001 Feb; 22(2):125-31. PubMed ID: 11741516
[TBL] [Abstract][Full Text] [Related]
22. Blockade of HERG channels by the class III antiarrhythmic azimilide: mode of action.
Busch AE; Eigenberger B; Jurkiewicz NK; Salata JJ; Pica A; Suessbrich H; Lang F
Br J Pharmacol; 1998 Jan; 123(1):23-30. PubMed ID: 9484850
[TBL] [Abstract][Full Text] [Related]
23. Blockade of HERG cardiac K+ current by antifungal drug miconazole.
Kikuchi K; Nagatomo T; Abe H; Kawakami K; Duff HJ; Makielski JC; January CT; Nakashima Y
Br J Pharmacol; 2005 Mar; 144(6):840-8. PubMed ID: 15778703
[TBL] [Abstract][Full Text] [Related]
24. Ranolazine inhibition of hERG potassium channels: drug-pore interactions and reduced potency against inactivation mutants.
Du C; Zhang Y; El Harchi A; Dempsey CE; Hancox JC
J Mol Cell Cardiol; 2014 Sep; 74(100):220-30. PubMed ID: 24877995
[TBL] [Abstract][Full Text] [Related]
25. Block of HERG current expressed in HEK293 cells by the Na+-channel blocker cibenzoline.
Hiramatsu M; Wu LM; Hirano Y; Kawano S; Furukawa T; Hiraoka M
Heart Vessels; 2004 May; 19(3):137-43. PubMed ID: 15168062
[TBL] [Abstract][Full Text] [Related]
26. Block of hERG K+ channel and prolongation of action potential duration by fluphenazine at submicromolar concentration.
Hong HK; Lee BH; Park MH; Lee SH; Chu D; Kim WJ; Choe H; Hee Choi B; Jo SH
Eur J Pharmacol; 2013 Feb; 702(1-3):165-73. PubMed ID: 23395964
[TBL] [Abstract][Full Text] [Related]
27. Discovery of a small molecule activator of the human ether-a-go-go-related gene (HERG) cardiac K+ channel.
Kang J; Chen XL; Wang H; Ji J; Cheng H; Incardona J; Reynolds W; Viviani F; Tabart M; Rampe D
Mol Pharmacol; 2005 Mar; 67(3):827-36. PubMed ID: 15548764
[TBL] [Abstract][Full Text] [Related]
28. Characterisation of recombinant HERG K+ channel blockade by the Class Ia antiarrhythmic drug procainamide.
Ridley JM; Milnes JT; Benest AV; Masters JD; Witchel HJ; Hancox JC
Biochem Biophys Res Commun; 2003 Jun; 306(2):388-93. PubMed ID: 12804575
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of the HERG channel by droperidol depends on channel gating and involves the S6 residue F656.
Luo T; Luo A; Liu M; Liu X
Anesth Analg; 2008 Apr; 106(4):1161-70, table of contents. PubMed ID: 18349188
[TBL] [Abstract][Full Text] [Related]
30. Inhibitory effect of the class III antiarrhythmic drug nifekalant on HERG channels: mode of action.
Kushida S; Ogura T; Komuro I; Nakaya H
Eur J Pharmacol; 2002 Dec; 457(1):19-27. PubMed ID: 12460639
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the effects of metoclopramide and domperidone on HERG channels.
Claassen S; Zünkler BJ
Pharmacology; 2005 Apr; 74(1):31-6. PubMed ID: 15640612
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of human ether-a-go-go-related gene K+ channel and IKr of guinea pig cardiomyocytes by antipsychotic drug trifluoperazine.
Choi SY; Koh YS; Jo SH
J Pharmacol Exp Ther; 2005 May; 313(2):888-95. PubMed ID: 15722405
[TBL] [Abstract][Full Text] [Related]
33. Local anesthetic interaction with human ether-a-go-go-related gene (HERG) channels: role of aromatic amino acids Y652 and F656.
Siebrands CC; Schmitt N; Friederich P
Anesthesiology; 2005 Jul; 103(1):102-12. PubMed ID: 15983462
[TBL] [Abstract][Full Text] [Related]
34. Antiarrhythmic drug carvedilol inhibits HERG potassium channels.
Karle CA; Kreye VA; Thomas D; Röckl K; Kathöfer S; Zhang W; Kiehn J
Cardiovasc Res; 2001 Feb; 49(2):361-70. PubMed ID: 11164846
[TBL] [Abstract][Full Text] [Related]
35. Block effect of capsaicin on hERG potassium currents is enhanced by S6 mutation at Y652.
Xing J; Ma J; Zhang P; Fan X
Eur J Pharmacol; 2010 Mar; 630(1-3):1-9. PubMed ID: 19903464
[TBL] [Abstract][Full Text] [Related]
36. Multiple mechanisms of hERG liability: K+ current inhibition, disruption of protein trafficking, and apoptosis induced by amoxapine.
Obers S; Staudacher I; Ficker E; Dennis A; Koschny R; Erdal H; Bloehs R; Kisselbach J; Karle CA; Schweizer PA; Katus HA; Thomas D
Naunyn Schmiedebergs Arch Pharmacol; 2010 May; 381(5):385-400. PubMed ID: 20229012
[TBL] [Abstract][Full Text] [Related]
37. Anesthetic drug midazolam inhibits cardiac human ether-à-go-go-related gene channels: mode of action.
Vonderlin N; Fischer F; Zitron E; Seyler C; Scherer D; Thomas D; Katus HA; Scholz EP
Drug Des Devel Ther; 2015; 9():867-77. PubMed ID: 25733807
[TBL] [Abstract][Full Text] [Related]
38. The low-potency, voltage-dependent HERG blocker propafenone--molecular determinants and drug trapping.
Witchel HJ; Dempsey CE; Sessions RB; Perry M; Milnes JT; Hancox JC; Mitcheson JS
Mol Pharmacol; 2004 Nov; 66(5):1201-12. PubMed ID: 15308760
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms of zolpidem-induced long QT syndrome: acute inhibition of recombinant hERG K(+) channels and action potential prolongation in human cardiomyocytes derived from induced pluripotent stem cells.
Jehle J; Ficker E; Wan X; Deschenes I; Kisselbach J; Wiedmann F; Staudacher I; Schmidt C; Schweizer PA; Becker R; Katus HA; Thomas D
Br J Pharmacol; 2013 Mar; 168(5):1215-29. PubMed ID: 23061993
[TBL] [Abstract][Full Text] [Related]
40. Block of hERG channel by ziprasidone: biophysical properties and molecular determinants.
Su Z; Chen J; Martin RL; McDermott JS; Cox BF; Gopalakrishnan M; Gintant GA
Biochem Pharmacol; 2006 Jan; 71(3):278-86. PubMed ID: 16325148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
